New drug cocktail shows promise for Tough-to-Treat ovarian cancer
NCT ID NCT02484404
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase 2 part checks if the combinations shrink tumors in recurrent ovarian cancer. About 268 adults with no standard treatment options are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab (immunotherapy) combined with olaparib (PARP inhibitor) or cediranib (anti-angiogenic drug)
- What this could lead to
- If successful, this could provide a new treatment option for advanced or recurrent ovarian cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial (phase 1/2) with a small number of participants, so results may not apply to all patients. The drug combinations can cause side effects like high blood pressure, fatigue, and immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Smartwatch could spot nerve damage before it starts
- Can your own immune cells beat advanced cancer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?